Sign in
CompletedPhase 1

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

Key facts

Who runs it
GlaxoSmithKline
Where
Australia4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 1
People taking part
127 people enrolled
Started
12 Aug 2025
Ended
6 May 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Pn-MAPS30plus
  • PCV20
Record updated
5 June 2026

Who can take part

Age
50 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol
  • Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any trial-specific procedure
  • Healthy male and female participants between and including 50 through 64 YOA at the time of Informed consent form (ICF) signature
  • Female participants of childbearing potential may be enrolled if they practice adequate contraception and have a negative pregnancy test prior to study intervention administration

Who cannot take part

  • Use of any investigational or non-registered product other than the study interventions during the period beginning 30 days before the study intervention administration
  • History of previous vaccination with any pneumococcal vaccine
  • Receipt of blood or plasma products or immunoglobulins, from 90 days before study intervention administration, or planned receipt within 30 days of study intervention administration
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial
  • History of microbiologically proven Invasive Pneumococcal Disease (IPD) caused by S. pneumoniae within the past 3 years
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s)
  • Any confirmed or suspected immunosuppressive or immunodeficient condition
  • Hypersensitivity to latex
  • Clinical conditions representing a contraindication to intramuscular vaccination, and blood collection
  • Documented history of Human immunodeficiency virus (HIV)-positive participant
  • Acute or unstable chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator
  • Recurrent history of uncontrolled neurological or any neuroinflammatory disorders
  • Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with trial participation
  • History of potential immune-mediated disorders (pIMDs)
  • Any other clinical condition that, might pose additional risk to the participant
  • History of chronic alcohol consumption and/or drug abuse, based on investigator judgment
  • Pregnant or lactating female participant

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.

The 2 groups in the trial

  • Pn-MAPS30plus GroupTreatment being tested

    Participants receive a single dose of Pn-MAPS30plus on Day 1.

    Treatment: Pn-MAPS30plus

  • PCV20 GroupExisting treatment, for comparison

    Participants receive a single dose of PCV20 on Day 1.

    Treatment: PCV20

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of An Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Record updated
5 June 2026